Clinical trials: Adenocarcinoma of the Prostate
Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma
Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
This phase II pilot trial studies how well bicalutamide and raloxifene hydrochloride work in treating patients with prostate cancer undergoing surgery.
- Trial name
- NCT03147196
- Testing
- Bicalutamide, Laboratory Biomarker Analysis, Questionnaire Administration
- Sponsor
- Mayo Clinic
Prostate Cancer
Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer
RATIONALE: Lenalidomide may stop the growth of prostate cancer by blocking blood flow to the tumor. GM-CSF may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00939510
- Testing
- sargramostim, lenalidomide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Robert Dreicer MD
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Hsp90 inhibitor STA-9090 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. This phase II trial is studying how well Hsp90 inhibitor STA-9090 works in treating patients with metastatic…
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01270880
- Testing
- Hsp90 inhibitor STA-9090, laboratory biomarker analysis, polymerase chain reaction
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC V7
Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or Low-Intermediate-Risk Prostate Cancer
This randomized phase III trial studies a diet and exercise program based on the Diabetes Prevention Program to promote weight loss and improve health in men with low-risk or low-intermediate-risk prostate cancer on active…
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC V7, Stage IIA Prostate Cancer AJCC v7
- Trial name
- PALS (NCT02454517)
- Testing
- Behavioral Dietary Intervention, Exercise Intervention, Informational Intervention
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- Fred Hutchinson Cancer Center
Prostate Cancer
Soy Supplements in Treating Patients Undergoing Surgery for Localized Prostate Cancer
RATIONALE: Dietary supplementation with soy may keep prostate cancer from growing in patients planning to undergo surgery. PURPOSE: This randomized phase II trial is studying a soy supplement to see how well it works compared to…
- Trial name
- NCT00345813
- Testing
- soy isoflavones, soy protein isolate
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
This is a single-center, open-label, non-randomized Phase I study of weekly Cabazitaxel with concurrent intensity modulated radiation therapy (IMRT) (A type of 3-dimensional radiation therapy that uses computer-generated images…
- Trial name
- NCT01420250
- Testing
- Cabazitaxel, Intensity Modulated Radiation Therapy (IMRT), Anti-Androgen Therapy: Bicalutamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Clear Cell Renal Carcinoma, Urothelial Carcinoma
Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors
This Phase Ib/II clinical study is an open-label, multi-cohort, two-stage trial designed to assess the safety and efficacy of different doses of TT-00420 tablets in combination with Toripalimab injection for treating patients…
- Conditions
- Clear Cell Renal Carcinoma, Urothelial Carcinoma, Metastatic Castration-resistant Prostate Cancer
- Trial name
- NCT06221774
- Testing
- TT-00420 + Toripalimab
- Where
- China
- Volunteers
- 42 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Cancer, Thyroid Cancer
Pharmaceutical Management in Targeted Radioligand Therapy
Targeted Radionuclide Therapy (TRT) is a treatment modality used in nuclear medicine to target cancer cells while preserving surrounding healthy tissues.
- Conditions
- Cancer, Thyroid Cancer, Metastatic Prostate Cancer, Neuroendocrine Tumor Carcinoid
- Trial name
- PharmTRT (NCT07389512)
- Where
- 3 sites in France
- Volunteers
- 600 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer
MEN-10755 in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of MEN-10755 in treating patients who have progressive…
- Trial name
- NCT00027781
- Testing
- sabarubicin
- Where
- 10 sites in Belgium, France and 4 more
- Volunteers
- 37 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer (Adenocarcinoma)
Effect of ADT and ARPI on Bone Loss of Patients with Prostate Cancer
This study aims to assess the impact of Androgen Deprivation Therapy (ADT) and Androgen Receptor Pathway Inhibitors (ARPI) on bone quality in patients with prostate cancer.
- Trial name
- NCT06838520
- Testing
- Bone health assessment
- Where
- 4 sites in China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
This is a first-in-human (FIH), open-label, Phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of ML261, an autologous potency enhanced anti-DLL3 CAR T cell therapy, in participants…
- Conditions
- Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Gastroenteropancreatic NEC (GEP NEC), Neuroendocrine Prostate Cancer (NEPC)
- Trial name
- NCT07488923
- Testing
- ML261
- Where
- 7 sites in United States
- Volunteers
- 110 people
- Sponsor
- Moonlight Bio, Inc
Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8
Computed Tomography-Guided Stereotactic Body Radiation Therapy With Intrafraction Motion Monitoring for the Treatment of Localized Prostate Cancer, ILLUSION Trial
This clinical trial studies the side effects of computed tomography (CT)-guided stereotactic body radiation therapy (SBRT) with intrafraction motion monitoring and to see how well it works in treating patients with prostate…
- Conditions
- Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
- Trial name
- ILLUSION (NCT06995053)
- Testing
- Biospecimen Collection, Computed Tomography, CT-guided Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer Metastatic, Castrate Resistant Prostate Cancer
Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients
This study aims to examine the use of high-intensity interval training (HIIT) and resistance training on docetaxel chemotherapy tolerability and toxicity in metastatic prostate cancer.
- Conditions
- Prostate Cancer Metastatic, Castrate Resistant Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Adenocarcinoma
- Trial name
- HIIT PCa (NCT05156372)
- Testing
- High Intensity Interval Training
- Where
- United States
- Sponsor
- The University of Texas Health Science Center at San Antonio
Adenocarcinoma of the Prostate, Prostate Cancer
Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer
The purpose of this study it to learn the effects (good or bad) that rosiglitazone has on patients and their prostate cancer. This study is going to look at what effects rosiglitazone has on prostate specific antigen (PSA) levels.
- Trial name
- NCT00182052
- Testing
- Rosiglitazone
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Carcinomas, Amyloidosis
B-Receptor Signaling in Cardiomyopathy
We hope to determine the importance of different genes (including B receptors) in anthracycline-induced cardiomyopathy. This has important benefits to patients exposed to anthracyclines, as this could help determine whether…
- Conditions
- Carcinomas, Amyloidosis, Anal Cancer, Anemia
- Trial name
- NCT01135849
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Daniel Bernstein
Adenocarcinoma of the Prostate
TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer
This is an open-label, single arm, two part adaptive design phase II trial of Olaparib in patients with advanced castration resistant prostate cancer.
- Trial name
- TOPARP (NCT01682772)
- Testing
- Olaparib
- Where
- 2 sites in United Kingdom
- Volunteers
- 148 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel
Drugs used in chemotherapy, such as SB-715992, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00096499
- Testing
- ispinesib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Prostate Cancer, Prostate Adenocarcinoma
Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer
The present study aims to optimize the use of systemic therapy relative to local tumor ablation in a prospective randomized clinical trial and to validate the existence and characterize the clinical and pathology phenotype of…
- Trial name
- NCT04031378
- Testing
- Single Dose Radiotherapy (24 Gy) to all detectable lesions, followed by observation, Single Dose Radiotherapy (24 Gy) to all detectable lesions followed by adjuvant systemic therapy for 6 months
- Where
- Portugal
- Volunteers
- 100 people
- Sponsor
- Fundacao Champalimaud
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer
This phase I trial tests the safety and side effects of cyclophosphamide given together with dexamethasone in treating patients with castration resistant prostate cancer that has spread to other places in the body (metastatic).
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) V8
- Trial name
- NCT05479578
- Testing
- Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Rashmi Verma, MD
Prostate Cancer
AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)
The goal of this clinical research study is learn how AMG208 may help to control prostate cancer that has spread to the bone. The safety of the drug will also be studied.
- Trial name
- NCT02420587
- Testing
- AMG 208, Questionnaire
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center